The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...
Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.
- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...
Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...
New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in multiple sclerosis (MS). PRLs are thought to capture a subset of chronic ...
Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells ...
ETHealthworld.com brings latest multiple sclerosis news, views and updates from all top sources for the Indian Health industry.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback